Close Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Close Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-495	Closed	-$27K	–	271
2025 Q3	$27K	Hold	495	–	–	﹤0.01%	200
2025 Q2	$27K	Hold	495	–	–	﹤0.01%	189
2025 Q1	$35K	Hold	495	–	–	﹤0.01%	167
2024 Q4	$33K	Hold	495	–	–	﹤0.01%	166
2024 Q3	$35K	Hold	495	–	–	﹤0.01%	178
2024 Q2	$41K	Buy	+495	New	+$41.2K	﹤0.01%	167
2022 Q4	–	Sell	-5	Closed	–	–	197
2022 Q3	$0	Hold	5	–	–	﹤0.01%	185
2022 Q2	$0	Sell	5 -645	-99%	-$51.4K	﹤0.01%	190
2022 Q1	$57K	Hold	650	–	–	﹤0.01%	119
2021 Q4	$57K	Hold	650	–	–	﹤0.01%	119
2021 Q3	$50K	Buy	650 +648	+32,400%	+$51.1K	﹤0.01%	122
2021 Q2	$0	Hold	2	–	–	﹤0.01%	202
2021 Q1	$0	Buy	+2	New	+$163	﹤0.01%	215

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Close Asset Management's BMRN Position: Q4 2025 in Review

Close Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 495 shares — an estimated $27K sold.

Close Asset Management first reported a position in BMRN in Q1 2021 and held it in 13 quarters. The position peaked at $57K in Q1 2022. 539 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

Close Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Close Asset Management sold 495 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $27K.
Close Asset Management first reported a position in BioMarin Pharmaceuticals in Q1 2021 and held it in 13 quarters.
Close Asset Management's BioMarin Pharmaceuticals position peaked at $57K in Q1 2022.
539 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Close Asset Management's 13F filing for Q4 2025, filed 10 Feb 2026.